cyrilzakka/clinical-trials huggingface dataset:
Long Distance Running Training by Older Adults

The goal of this project is to understand the effect of regular practice of long distance running on the posture and movement control of older adults.

For such, the investigators will conduct an experiment with longitudinal design where sedentary elderly individuals will be trained in long distance running for about 4 months.

In a study the investigators conducted about elderly runners, the main observed difference by the first time was that elderly individuals present greater foot abduction (toe-out) during running than young adults. This alteration has been observed in elderly individuals in general during walking, and identified as a protective mechanism to not overload the medial compartment of the knee joint. It is also known that elderly individuals present a different joint torque distribution in the lower limbs during walking in comparison with young adults. However, it's not known the relation between the movement patterns, particularly the foot abduction pattern, and the mechanical load on the knee joint during running by elderly individuals and neither the longitudinal effect of running practice on this relation and on the mechanical joint load distribution. Another unknown aspect is the actual effect of the running practice on the posture control of elderly individuals.

With this project, the investigators want to understand why elderly individuals change their movement pattern during running, to determine for the same subjects if this altered pattern is also present during walking and standing, and to determine the effect of running practice on the elderly posture control. Our hypotheses are that the strategy of greater foot abduction is present in all movement tasks and that the use of this strategy is related to the integrity of the knee joint, even considering the highly active elderly individuals and that the practice of running contributes for a better postural control in this population.

These findings will contribute for a greater understanding of the benefits of the practice of running and the adaptations developed by the elderly runners and in this way to contribute for the prescription of this activity to the elderly population.

Eligibility Criteria:
Inclusion Criteria:

* Sedentary
* Independent bipedal locomotion

Exclusion Criteria:

* Inapt for practicing physical activity
* Severe alteration of the muscle-skeletal system
* Cognitive or neurological deficit
* Use of orthosis for locomotion
Swallowing Dynamic of Implant Retained Mandibular Overdentures

This Randomized clinical study was conducted to compare between two-implant versus single implant-retained mandibular overdenture regarding swallowing dynamic using The Test of Mastication and Swallowing Solids (TOMASS) and the Timed Water Swallow Test (TWST)

There are lack of studies comparing single and two implant-retained mandibular overdentures regarding swallowing dynamic. This Randomized clinical study aimed to compare the effect of two treatment modalities of mandibular implant over denture on the swallowing dynamic.

8 completely edentulous patients were selected from the Out-Patient Clinic of Prosthodontics' Department, Faculty of Dentistry, Mansoura University seeking prosthetic rehabilitation. All patients were randomly distributed into two equal groups; Group I (Patients received two-implant mandibular overdenture with locator attachment) and Group II ( Patients received single implant mandibular overdenture with locator attachment) All subjects received a newly carefully constructed complete dentures and then the lower dentures were changed into mandibular implant retained overdentures using locator attachments by placing two implants on the mandibular canine regions for group I and single midline implant for group II.

Swallowing dynamic was evaluated after 3 months of complete denture insertion for both groups. After mandibular overdenture insertion swallowing dynamic was evaluated 2 weeks after insertion and three months after overdenture insertion for both groups.

Eligibility Criteria:
Inclusion Criteria:

* Free from any systemic disease.
* Free from any medical or surgical conditions that cause dysphagia (swallowing problems).
* A sufficient residual alveolar bone quantity (height and width). This was verified by a CT scan using cone-beam computed tomography for each patient.
* All patients had sufficient bone either D2 or D3 by measuring the Hounsfield unit on CBCT scan.
* Residual ridges are covered by firm healthy mucosa.
* Class I maxilla-mandibular relationship.
* sufficient inter-arch space and restorative space for locator retained mandibular overdenture.

Exclusion Criteria:

* Patient with absolute contraindications for implant placement such as active cancer, immunosuppression, bleeding issues, and metabolic diseases that directly affect the bone such as osteoporosis, and hyperparathyroidism.
* Patients with relative contraindication: history of para functional habits such as bruxism, clenching, and bad habits such as smoking and alcoholism, uncontrolled diabetic patients.
* Patients with local contraindications for implant placement due to localized bone defects.
* Non-cooperative patients who don't follow instructions during and after the operation.
Single-cycle Remote Ischemic Preconditioning and Postconditioning for Prevention of Contrast-Induced Nephropathy

This trial is a 2 x 2 factorial design, double-blinded, randomized controlled trial to evaluate efficacy and safety of remote ischemic preconditioning and postconditioning for prevention of contrast-induced acute kidney injury in patient undergoing coronary angiography and angioplasty

randomized controlled trial

Eligibility Criteria:
Inclusion Criteria:

* The patient have indication for coronary angiography or angioplasty.
* Impaired renal function with reduced eGFR \< 60 ml/min/1.73 m2 by CKD-EPI equation.
* Written informed consent.

Exclusion Criteria:

* History of contrast allergy.
* The patient had end-stage renal failure with the need for hemodialysis.
* The patient take medications that affect the kidneys function within 48 hours before study.
* The patient had acute kidney injury from any cause.
* The patient was received contrast media within 2 weeks before study.
* The patient had cardiac arrest or shock.
* The patient had peripheral arterial disease (PAD)
* Pregnancy
* Refused to study
Short-term Study of Combination Treatment of Escitalopram and Gaboxadol in Major Depressive Disorder

To compare the efficacy of escitalopram fixed dose 20 mg/day in combination with fixed doses of gaboxadol (5 and 10 mg/day) versus escitalopram fixed dose 20 mg/day after 8 weeks of treatment in patients with Major Depressive Disorder

Subjects participating in this study will be respectively randomised (1:2:2:2) to receive either:

* placebo or
* escitalopram 20 mg/day or
* escitalopram 20 mg/day in combination with gaboxadol 5 mg/day or
* escitalopram 20 mg/day in combination with gaboxadol 10 mg/day

Eligibility Criteria:
Inclusion Criteria:

Clinical Diagnosis of MDD according to DSM-IV-TR criteria:

* With reported duration of the current major depressive episode of at least 3 months
* With MADRS total score of at least 30

Exclusion Criteria:

The patient has 1 or more of the following:

* Any current psychiatric disorder other than MDD as defined in the DSM-IV-TR
* Current or past history of: manic or hypomanic episode, schizophrenia, or any other psychotic disorder, including major depression with psychotic features, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR
* Any substance disorder (except nicotine and caffeine) within the previous 6 months as defined in the DSM-IV-TR
* Presence or history of a clinically significant neurological disorder (including epilepsy)
* Neurodegenerative disorder (Alzheimer disease, Parkinson disease, multiple sclerosis, Huntington disease, etc)
* Any Axis II disorder that might compromise the study
* Previous use of hallucinogenic drug

The patient has a significant risk of suicide according to the investigator's opinion, or has a score \>=5 on item 10 (suicidal thoughts) of the MADRS, or has made a suicide attempt in the previous 12 months.
Intraprocedural Assessment of Ablation Margins Using Computed Tomography Co-registration in Primary Liver Tumor Treatment With Percutaneous Ablation

A pre- and postablation scan will be made intraprocedurally to investigate the feasibility of intraprocedural ablation verification assessment using coregistration software


Eligibility Criteria:
Inclusion Criteria:

* Age 18 yrs or above
* HCC very early (0) or early stage (A) according to the BCLC staging system
* Either de novo or recurrent HCC (prior locoregional therapy is allowed in the study)
* Candidate for percutaneous thermal ablation as discussed in a multidisciplinary tumor board. Ablation as 'bridge-to-transplant' is allowed in the study

Exclusion Criteria:

* Estimated GFR \<30 ml/min
* Morbid obesitas or any pulmonary condition that is a contraindication to prolonged apnea and high jet-ventilation
* Child Pugh C
* Portal vein tumor invasion
* Extrahepatic metastasis
* Uncorrectable coagulopathy
* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
* Inability or unwillingness to give informed consent
FLAIR™ Delivery System Study

The objective of this clinical study is to evaluate the performance of the Optimized FLAIR™ Delivery System.


Eligibility Criteria:
Inclusion Criteria:

* The subject is either a male or non-pregnant female ≥ 18 years old.
* The subject has been properly informed about the study per IRB requirements, and has signed and dated the IRB-approved ICF.
* The subject is willing to comply with the protocol requirements and can be contacted by telephone.
* The subject has a synthetic AV access graft located in an arm that has been implanted for \> 30 days and has undergone at least one successful dialysis session prior to the index procedure.
* Angiographic evidence indicates that the subject has a stenosis of \>50% located at the graft-vein anastomosis of the subject's synthetic AV access graft.
* The target lesion is estimated to be ≤ 7 cm in length by angiography prior to performance of any interventional procedures.
* The entire target lesion is located within 7 cm of the graft-vein anastomosis, as verified by angiography, such that approximately 1 cm of the FLAIR™ Endovascular Stent Graft will extend into non-diseased vein and approximately 1 cm but no more than 2 cm of the FLAIR™ Endovascular Stent Graft will extend into non-diseased AV graft.
* Graft diameter at the deployment site is between 5 mm and 8 mm, as verified by angiography.
* Full expansion of an appropriately sized angioplasty balloon, in the operator's judgment, can be achieved during primary angioplasty.

Exclusion Criteria:

* The subject has a life expectancy of \< 6 months.
* The presence of a previously placed stent and/or stent graft located in the treatment area. The treatment area is defined as the entire target lesion and 1 cm of landing zone into both non-diseased AV graft and non-diseased vein.
* The subject has an infected AV access graft or other infection.
* The location of the target lesion would require that the FLAIR™ Endovascular Stent Graft be deployed fully across the elbow joint.
* The location of the target lesion would require that the FLAIR™ Endovascular Stent Graft cross an angle (between the outflow vein and synthetic AV access graft) that is \> 90 degrees.
* The subject has an uncorrected blood coagulation disorder.
* The subject has a known allergy or sensitivity to contrast media which cannot be adequately pre-medicated.
* Subject is currently enrolled or scheduled to be enrolled in other investigations that conflict with follow-up testing or confounds data in this trial.
* The subject has a known hypersensitivity to nickel-titanium.
Microbiological Characterization and Nasal Carriage Rates of Methicillin Resistant Staphylococcus Aureus (MRSA) in Vancouver Downtown Eastside

We plan to compare data from 300 nasal swab in Vancouver's Downtown Eastside taken in 2001 to data obtained in 2005. The nasal carriage rate of MRSA and the specific characteristic of each MRSA found will be analyzed. A limited amount of associated information will be obtained

MRSA samples will be characterized by pulse field gel electropheresis. An 9 item questionnaire will be administered.

Eligibility Criteria:
Inclusion Criteria:

Patient had a microbiological sample submitted from the emergency department of the study hospital from 2001- 2005 which grew MRSA.

Exclusion Criteria:
Using Game-based Exercise to Improve Balance in Cancer Patients

Cancer patients with chemotherapy-induced peripheral neuropathy (CIPN) have deficits in sensory and motor skills leading to inappropriate proprioceptive feedback, impaired postural control and high fall risk. This study will investigate the acceptability and effect of an interactive motor adaptation balance training program based on wearable sensors for improving balance in older cancer patients with CIPN. Cancer patients with confirmed CIPN will be recruited and will be randomized to either intervention (IG) or control (CG) group and followed for 6 months. The intervention group will take part in a 6-week balance training program twice per week in either their home or in clinic (based on subject preference) under the supervision of a qualified research staff member. This intervention includes interactive game-based balance training including repetitive weight shifting and virtual obstacle crossing tasks. Wearable sensors will provide real-time visual/auditory feedback from foot and ankle position and allowed perception of motor-errors during each motor-action. The control group will be instructed to complete a supervised foot and ankle exercise without using sensor technology. Changes in balance, gait, and physical activity, and number of falls will be compared pre- and post-intervention, as well as 3 and 6 month post intervention. Investigators hypothesize that patients receiving sensor-based exercise training will benefit more compared to group receiving conventional non-technology home-based training in terms of improving functional performance and reducing falls.


Eligibility Criteria:
Inclusion Criteria:

* Cancer patients
* Men or women aged 55 years or older
* Patients undergoing neurotoxic chemotherapy (agents including platinums, vinca alkaloids, taxanes, proteasome inhibitors and interferons)
* Confirmed peripheral neuropathy (VPT\>25) will be eligible to participate

Exclusion Criteria:

* Subjects will be excluded if they have undergone surgery in the last 6-8 weeks
* Have Parkinson's Disease
* Stroke patients
* Dementia patients
* Have an active foot ulcer
* Have an active infection
* Lower extremity major amputation
* Patient is taking medications unrelated to cancer treatment that may affect balance and gait
* Patient has other medical conditions that may affect their balance and gait
* Patient is unable to ambulate without assistance.
Effect of Inhaled Fentanyl on Dyspnea and Exercise Tolerance in Chronic Obstructive Pulmonary Disease (COPD)

Breathing discomfort (dyspnea) and activity limitation are dominant symptoms of chronic obstructive pulmonary disease (COPD) and contribute to poor health-related quality of life in this population. Several small, uncontrolled studies and published case reports have provided evidence that inhaled fentanyl, a powerful pain relieving (opioid) medication, may be used to effectively reduce breathing discomfort in patients with advanced disease. However, the mechanisms of this improvement remain unclear. Therefore, the investigators plan to conduct the first randomized, double-blind, placebo-controlled, crossover study designed to explore the possible mechanisms of action of inhaled fentanyl on activity-related dyspnea and exercise performance in patients with advanced COPD.


Eligibility Criteria:
Inclusion Criteria:

* Post-bronchodilator forced expiratory volume in 1 sec (FEV1) 30-79% predicted, FEV1/forced vital capacity (FVC) ratio \<70%;
* Clinically stable as defined by no changes in medication dosage or frequency of administration with no exacerbations or hospital admissions in the preceding 6 weeks;
* A cigarette smoking history ≥20 pack-years;
* Significant chronic activity-related dyspnea as defined by a Baseline Dyspnea Index focal score ≤ 6;
* Body mass index (BMI) between 18.5 and 30.0 kg/m2;
* Able to perform all study procedures and provide/sign informed consent.

Exclusion Criteria:

* A diffusing capacity of the lung for carbon monoxide (DLCO) \<40 %predicted;
* Presence of active cardiopulmonary disease other than COPD that could contribute to dyspnea and exercise limitation;
* Clinical diagnosis of sleep disordered breathing;
* A history/clinical evidence of asthma, atopy and/or nasal polyps;
* History of allergy or adverse reaction to fentanyl;
* Presence of important contraindications to clinical exercise testing, including inability to exercise because of neuromuscular or musculoskeletal disease(s);
* Use of daytime oxygen or exercise-induced arterial oxygen desaturation to \<80% on room air;
* Use of antidepressant drugs (i.e., monoamine oxidase inhibitors, serotonin reuptake inhibitors) in previous 2 weeks;
* Use of opioid or pain relieving drugs (e.g., morphine, fentanyl, oxycodone, hydromorphone, methadone, levorphanol, codeine, hydrocodone, meperidine) in previous 4 weeks.
TreadWill, an Automated Intervention for Depressive Symptoms

TreadWill is a fully automated digital intervention that provides a multi-modal treatment for depressive symptoms. It includes:

1. Slides and interactive text-based conversations based on Cognitive Behavioral Therapy (CBT);
2. Mindfulness videos;
3. Game-based Cognitive Bias Modification paradigms;
4. An empathetic chatbot. This study's primary aim is to test the differential effectiveness of this full-featured version of TreadWill compared to a text-based CBT program.

TreadWill is an online tool to deliver automated intervention for depressive symptoms. TreadWill helps the participants learn the concepts of Cognitive Behavioral Therapy (CBT), and practice mindfulness in an interactive manner. It also has games based on Cognitive Bias Modification (CBM) and an empathetic chatbot. We hypothesize that participants using TreadWill will show a significant reduction in depressive symptoms and will show engagement with the program. To test this hypothesis, we are conducting a randomized controlled trial. We will randomize participants into three groups: experimental, active control, and waitlist. Participants randomized to the experimental group will get access to the full-featured version of TreadWill as described above. Participants randomized to the active control group will have access to a limited version of TreadWill designed to deliver basic CBT in plain text format. The waitlisted participants will be put on a waitlist for 6 weeks.

Eligibility Criteria:
Inclusion Criteria:

* Fluent in English
* PHQ-9 Score from 5 to 19
* Access to an internet-enabled Android smartphone
* Plan to use TreadWill in Google Chrome browser
* Agree to allow notifications from TreadWill
* Agree to add TreadWill to Home screen
* Have email on one of the HTML-enabled platforms including Gmail, Outlook, Yahoo, Rediffmail, AOL, Hotmail.

Exclusion Criteria:

* Suicide ideation (score greater than 0 on the 9th question of PHQ-9 and score greater than 4 on SIQ)
* Unemployed
* Current or previous diagnosis of bipolar disorder/manic-depressive disorder or psychosis
* Prospective participants who say they only want to check out the program and do not plan to complete it are excluded.
* Used an earlier version of TreadWill
A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea

The purpose of this study is to estimate the proportion of all adverse events (AEs) including serious adverse events (SAEs) occurring with the use of brigatinib among adult participants who have been administered brigatinib as per the approved indications.

This is a prospective observational post-marketing surveillance study of participants with ALK-positive NSCLC who initiate treatment for the first time with brigatinib in a routine clinical practical setting. The study will characterize the safety and effectiveness of brigatinib for its approved indications under real world use.

The study will enroll approximately 257 participants. The data will be prospectively collected, at the centers from routinely scheduled and emergency visits until end of follow up, and recorded into electronic case report forms (e-CRFs). All participants will be assigned to a single observational cohort.

This multi-center study will be conducted in the South Korea. The overall duration of this study is approximately 6 years. Data will be collected over and up to a 24 month-surveillance period (per participant) once enrolled.

Eligibility Criteria:
Inclusion Criteria:

1. With ALK-positive advanced or metastatic NSCLC.
2. Who initiate brigatinib for the first time.

Exclusion Criteria:

1. Treated with brigatinib outside of the locally approved label in Korea.
2. Whom brigatinib is contraindicated as per product label.
3. Participating in other clinical trials of NSCLC treatment.
Bone Mesenchymal Stem Cell (BMSC) Transplantation in Liver Cirrhosis Via Portal Vein

The objective of this study is to evaluate the therapeutic efficacy of autologous bone marrow mesenchymal stem cells (BMSCs) transplantation via portal vein in patients with early and middle stage of liver cirrhosis on the basis of HBV infection. The evaluation of the efficacy includes the level of serum alanine aminotransferase (ALT), aspartate aminotransferase(AST), total bilirubin (TB),prothrombin time (PT), albumin (ALB), prealbumin(PA), precollagenⅢ(PCⅢ), collagenⅣ(Ⅳ-C), laminin(LN), hyaluronidase(HN), liver histological improvement before and 1 week to 1 year after transplantation. Child-Pugh scores and clinical symptoms were also observed simultaneously.


Eligibility Criteria:
Inclusion Criteria:

* Aged 18\~60 years.
* Serum HBsAg positive.
* Ultrasonographic evidences of cirrhosis.

Exclusion Criteria:

* history of moderate to severe hepatic encephalopathy or variceal bleeding during the last two months before enrolment.
* Prothrombin time is less than 30s.
* Cirrhosis caused by other reasons except HBV infection.
* Severe problems in other vital organs(e.g.the heart,renal or lungs).
* Liver tumor on ultrasonography, CT or MRI examination.
* Pregnant or lactating women.
* Imaging evidences of vascular thromboses.
Methadone in Post-Herpetic Neuralgia Pain

Neuropathic pain is a common condition and affecting 40 to 70% of the general population. Post-herpetic neuralgia is a condition almost complex and requires a multi modal treatment. Aim: This is a pilot proof-of-principle study designed to evaluate the use of low-dose methadone in post-herpetic neuralgia patients who remained refractory after first and second line treatment for post-herpetic neuralgia (PHN) and had indication for the association of an opioid agent to their current drug regimen.


Eligibility Criteria:
Inclusion Criteria:

* Patients with chronic (\>6 months) symptomatic PHN
* with visual analogical scale \>40/100mm
* use of first and second line drugs (tricyclic antidepressants, venlafaxine and gabapentinoids)

Exclusion Criteria:

* Don't full the criteria above